biostudies-literatureUnknown83(11)Muanda FTRéseau Québécois de recherche sur l&apos;usage des médicaments<h4>Aims</h4>Few studies have investigated the link between individual antibiotics and major congenital malformations (MCMs) including specific malformations owing to small sample size. We aimed to quantify the association between exposure to gestational antibiotic and the risk of MCMs.<h4>Methods</h4>Using the Quebec pregnancy cohort (1998-2008), we included a total of 139 938 liveborn singleton alive whose mothers were covered by the "Régie de l'assurance maladie du Québec" drug plan for at least 12 months before and during pregnancy. Antibiotic exposure was assessed in the first trimester and MCMs were identified within the first year of life.<h4>Results</h4>After adjusting for potential confounders, clindamycin exposure was associated with an increased risk of MCMs (aOR 1.34, 95% CI 1.British journal of clinical pharmacology2557-2571https://www.ebi.ac.uk/biostudies/studies/S-EPMC5651310biostudies-literatureUse of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study.PMC5651310Muanda FTBerard ASheehy OfalseUse of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study.<h4>Aims</h4>Few studies have investigated the link between individual antibiotics and major congenital malformations (MCMs) including specific malformations owing to small sample size. We aimed to quantify the association between exposure to gestational antibiotic and the risk of MCMs.<h4>Methods</h4>Using the Quebec pregnancy cohort (1998-2008), we included a total of 139 938 liveborn singleton alive whose mothers were covered by the "Régie de l'assurance maladie du Québec" drug plan for at least 12 months before and during pregnancy. Antibiotic exposure was assessed in the first trimester and MCMs were identified within the first year of life.<h4>Results</h4>After adjusting for potential confounders, clindamycin exposure was associated with an increased risk of MCMs (aOR 1.34, 95% CI 1.2017-01-01T00:00:00Z2017 Nov2025-04-26T09:28:11.65Z2019-03-27T00:04:40ZS-EPMC56513102872217110.1111/bcp.13364